RxDoctor Payments Data

Ravi Kumar Singareddy, MD

Psychiatry · Suwanee, GANPI 1407809122

Payments from drug & device makers

$1,718in general payments, 2019–2025

Across 52 payments — averaging $33.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$708
  • Brainsway USA Inc$117
  • Eisai Inc.$115
  • Noven Pharmaceuticals, Inc.$114
  • AbbVie$109
  • Neurocrine Biosciences, Inc.$107
  • plus $447 from 12 others

What the payments were for

  • Food & beverage$1,718100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,718 in reported general payments places this provider in the 70th percentile of 900 psychiatry providers in Georgia.

See all psychiatry providers in Georgia

Medicare billing

Part B allowed, 2024
$194,700
Medicare patients
168
Services billed
1,441

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate11$92,733
Paliperidone ErPaliperidone19$11,719
Duloxetine Hcl125$4,562
Aripiprazole76$3,989
Bupropion XlBupropion Hcl160$3,112
Mirtazapine141$2,899
Buspirone Hcl218$2,565
Clomipramine Hcl14$2,503
Ramelteon13$2,126
Quetiapine Fumarate153$2,058
Olanzapine87$1,685
Carbamazepine ErCarbamazepine13$1,470
Trazodone Hcl200$1,301
Divalproex Sodium52$1,267
Escitalopram Oxalate141$1,247

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$107$92,73311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 900 psychiatry providers in Georgia.

Other psychiatry in Suwanee

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →